Our Bronx VA study site continues to actively screen for new participants. Enrollment is continuing for this Phase 2, open-label study on the effectiveness of MDMA-assisted therapy in U.S. Veterans with …
As of August 8, 2022, a total of five participants have been enrolled and the Bronx VA site continues to actively screen for new participants. Enrollment is continuing for this Phase 2, open-label study …
Enrollment is continuing for our Phase 2, open-label study on the effectiveness of MDMA-assisted therapy in U.S. Veterans with chronic PTSD. This study is a comparative study that assesses two versus three …
As of early May, one subject has been treated and four subjects are being evaluated for treatment in the MAPS-sponsored Phase 2, open-label study of the comparative effectiveness of two vs. three MDMA-assisted …
As of April 15, 2022, the second and third participants are screening for treatment in the MAPS-sponsored Phase 2, open-label study of the comparative effectiveness of two vs. three MDMA-assisted therapy …
On February 3, 2022, the first participant was treated in the MAPS-sponsored Phase 2, open-label study of the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with …
MAPS is sponsoring a Phase 2, open-label protocol to study the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with PTSD at the James J. Peters Veterans Affairs (VA) …
MAPS is sponsoring a Phase 2, open-label protocol to study the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with PTSD at the James J. Peters Veterans Affairs (VA) …
MAPS is sponsoring a Phase 2, open-label protocol to study the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with PTSD at the James J. Peters Veterans Affairs (VA) …
On August 17 and 18, 2021, researchers from MAPS Public Benefit Corporation (MAPS PBC) conducted the official site initiation visit for the MAPS-sponsored Phase 2 study of MDMA-assisted therapy for U.S. …
The Institutional Review Board (IRB) approved MAPS’ protocol for a Phase 2, open-label randomized controlled comparative study on the effectiveness of MDMA-assisted therapy in U.S. Veterans with chronic …
MAPS is delighted to report an important milestone towards a randomized clinical trial at the Veterans Affairs (VA) Administration, where so many of our nation’s veterans are treated for PTSD. The …
